ClinicalTrials.gg
CompletedNCT03407118Updated May 1, 2020Results posted

A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus

A Phase 1 interventional study of LY900014 and Insulin Lispro in Diabetes Mellitus, Type 1, sponsored by Eli Lilly and Company. Completed at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-01.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.

Enrollment
42nd of 69
31 · median 38
Started
2018
with 7 others
Phase 1
22 of 69
none open now
Registered
42nd of 69
by date
Lead sponsor
31 of 69
Eli Lilly and Company

Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 42nd largest by enrollment, is one of 8 that started in 2018, is one of 22 in phase 1, and was the 42nd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Insulin Lispro

Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This study will compare LY900014, a drug that lowers blood sugar, with insulin lispro (Humalog). Both drugs will be given by injection under the skin of the abdomen. This study will be conducted in participants with type 1 diabetes to investigate how quickly and how much LY900014 is absorbed and the effect of LY900014 on blood sugar levels in comparison with insulin lispro. The study will last about 3 to 6 weeks for each participant, not including screening.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are Japanese male or female participant with a diagnosis of T1DM, based on the World Health Organization classification, for at least 1 year prior to screening
  • Have a (BMI) of 18.5 to 30.0 kilograms per square meter (kg/m²)
  • Have a \<9.0% at screening

Exclusion criteria

Exclusion Criteria:

  • Have, except for current regimen of insulin therapy and concomitant medication(s), regular use of or intended use of any over-the-counter or prescription medications or nutritional supplements that treat hyperglycemia or insulin resistance or that promote weight loss within 14 days before dosing
  • Are receiving chronic (lasting longer than 14 consecutive days) systemic or inhaled therapy (excluding topical, intra-articular, and intraocular preparations), or have received such therapy within the 4 weeks before screening
  • Have a history of renal impairment (exclusion only if estimated [GFR] \<60 milliliters/minute/1.73 square meters [GFR is estimated according to a formula recommended by the Japanese Society of Nephrology]), or have a serum creatinine level ≥126 micromoles per liter (μmol/L) (>1.42 milligrams per deciliter [mg/dL]) (male) or ≥111 μmol/L (>1.25 mg/dL) (female)
  • Have a history of deep vein thrombosis of the leg, or repeated episodes of deep leg vein thrombosis in first-degree relatives (parents, siblings, or children), as determined by the investigator
  • Have proliferative retinopathy or maculopathy and/or severe neuropathy; in particular, autonomic neuropathy, as determined by the investigator based on a recent (\<1.5 years) ophthalmologic examination
  • Have had any significant changes in insulin regimen and/or unstable blood glucose control within the past 3 months prior to screening, as determined by the investigator
  • Require daily insulin treatment >1.5 units per kilogram (U/kg)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    LY900014

    Single, 15 units (U)LY900014 administered subcutaneously (SC) in one of two study periods in Japanese Patients With Type 1 Diabetes Mellitus (T1DM).

    Drug: LY900014

  • Active comparator
    Insulin Lispro (Humalog)

    Single, 15 U insulin lispro administered SC in one of two study periods in Japanese Patients With Type 1 Diabetes Mellitus.

    Drug: Insulin Lispro

Interventions

  • Administered SC.

    Also known as: Ultra-Rapid Lispro

  • Administered SC.

    Also known as: LY275585, Humalog

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to 10 Hours (AUC 0-10h) Following Administration of Each Treatment Arm

    PK: Insulin Lispro AUC from time zero to 10 hours

    Time frame: Predose, 5 minutes (min), 10 min, 15 min, 20 min, 25 min, 30 min, 35 min, 40 min, 45 min, 50 min, 55 min, 60 min, 70 min, 90 min, 120 min, 150 min, 180 min, 240 min, 300 min, 360 min, 420 min, 480 min, 540 min, and 600 min postdose

Secondary outcomes

  1. Glucodynamics (GD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp Following Administration of Each Treatment Arm

    Gtot Over Duration of Clamp for Each Treatment Arm. Gtot is the total glucose infusion over the clamp duration (10 hours) and is used to measure the study drug action over time as measured by the euglycemic clamp (EC) procedure. During the euglycemic clamp procedure, blood glucose concentrations are held constant after the administration of study treatment by adjusting the exogenous glucose infusion rate.

    Time frame: Predose, every minute from run-in and for the duration of the EC until up to 10 hours postdose

07

Results

Posted May 1, 2020

Participant flow

Period 1
Participant flow — Period 1
MilestoneLY900014\Insulin Lispro (Humalog)Insulin Lispro (Humalog)\LY900014
Started1417
Received at least 1 dose of study drug1417
Completed1417
Not completed00
Period 2
Participant flow — Period 2
MilestoneLY900014\Insulin Lispro (Humalog)Insulin Lispro (Humalog)\LY900014
Started1417
Received at least 1 dose of study drug1317
Completed1317
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to 10 Hours (AUC 0-10h) Following Administration of Each Treatment Arm

PK: Insulin Lispro AUC from time zero to 10 hours

Time frame:
Predose, 5 minutes (min), 10 min, 15 min, 20 min, 25 min, 30 min, 35 min, 40 min, 45 min, 50 min, 55 min, 60 min, 70 min, 90 min, 120 min, 150 min, 180 min, 240 min, 300 min, 360 min, 420 min, 480 min, 540 min, and 600 min postdose
Reported as:
Geometric mean · picomols times hour per Liter
Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to 10 Hours (AUC 0-10h) Following Administration of Each Treatment Arm
picomols times hour per Liter15 U LY90001415 U Insulin Lispro (Humalog)
Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to 10 Hours (AUC 0-10h) Following Administration of Each Treatment Arm1930 ± 591980 ± 20
Statistical analysis
  • 15 U LY900014 vs 15 U Insulin Lispro (Humalog) · Ratio of least square means: 0.967 · 95% CI 0.803 to 1.17
SecondaryGlucodynamics (GD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp Following Administration of Each Treatment Arm

Gtot Over Duration of Clamp for Each Treatment Arm. Gtot is the total glucose infusion over the clamp duration (10 hours) and is used to measure the study drug action over time as measured by the euglycemic clamp (EC) procedure. During the euglycemic clamp procedure, blood glucose concentrations are held constant after the administration of study treatment by adjusting the exogenous glucose infusion rate.

Time frame:
Predose, every minute from run-in and for the duration of the EC until up to 10 hours postdose
Reported as:
Geometric mean · milligrams per kilogram
Glucodynamics (GD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp Following Administration of Each Treatment Arm
milligrams per kilogram15 U LY90001415 U Insulin Lispro (Humalog)
Glucodynamics (GD): Total Amount of Glucose Infused (Gtot) Over Duration of Clamp Following Administration of Each Treatment Arm1190 ± 541250 ± 34

Adverse events

Collected over Baseline up to 56 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY9000140/31 (0%)0/31 (0%)6/31 (19.4%)
Insulin Lispro (Humalog)0/30 (0%)0/30 (0%)7/30 (23.3%)
Most frequent other events
Most frequent other events
EventLY900014Insulin Lispro (Humalog)
HeadacheNervous system disorders3/314/30
nauseaGastrointestinal disorders3/311/30
vomitingGastrointestinal disorders2/312/30
Back painMusculoskeletal and connective tissue disorders1/312/30

Baseline characteristics

All randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)All Participants
Mean39.5 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female18
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino0
Not Hispanic or Latino31
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian31
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)All Participants
Japan31
Weight
Weight(kilograms)All Participants
Mean59.62 ± 8.29
Height
Height(centimeters)All Participants
Mean161.35 ± 7.44
Body Mass Index
Body Mass Index(kilograms per meter squared)All Participants
Mean22.85 ± 2.44
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Fukuoka, 812-0025, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Jun 2018, 4 months.

Results were first posted in May 2020, 1 year 10 months after primary completion.

Of 98 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 4 months is below that.

Counting every sponsor, half of 153 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2018
First posted
Jan 23, 2018
StartActual
Feb 17, 2018
Primary completionActual
Jun 23, 2018
CompletionActual
Jul 12, 2018
Results first posted
May 1, 2020
Last update
May 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03407118
Responsible party
Sponsor
First posted
Jan 23, 2018
Start date
Feb 17, 2018
Primary completion
Jun 23, 2018
Completion
Jul 12, 2018
Results posted
May 1, 2020
Last update
May 1, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Lispro

Start the discussion